Proven Cancer Research Experts + Revolutionary AI
Rakovina Therapeutics Inc. (🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD ) is combining renowed leaders in oncology and cutting-edge AI to compress traditional drug discovery timelines and accelerate life-saving cancer treatments.
Download Investor Kit — It’s free
Learn More About Our Research
WORLD-CLASS ADVISOR- $142M TRACK RECORD
BREAKTHROUGH TECHNOLOGY - DEEP DOCKING™️ CREATOR
STRATEGIC ADVANTAGE - EXCLUSIVE AI PLATFORM RIGHTS
VALIDATED APPROACH- PROVEN COMMERCiAL SUCCESS
Massive AI Investments Reshape Healthcare
The integration of artificial intelligence into pharmaceutical R&D has sparked a race for multi-billion-dollar partnerships and massive infrastructure commitments, highlighting the major transformation happening across the industry.
$500B U.S. AI Infrastructure Plan
OpenAI, SoftBank, Oracle joint venture "Stargate"
20 advanced AI data centers planned
Healthcare AI applications prioritized
Source:
Reuters
AstraZeneca's $5.33B China AI Deal
$110M upfront to CSPC Pharmaceutical
Up to $5.22B in milestone payments
Focus: AI-driven chronic disease solutions
Source:
Reuters
Recent Billion-Dollar AI Drug Deals
Novartis-Artios: $1.5B for PARP inhibitors
Sanofi-Remix: $1.2B for ATR inhibitors
Multiple $1B+ partnerships in DNA-damage response
Source:
Rakovina Therapeutics
These blockbuster deals are more than headlines—they reflect the urgency with which the industry is adopting AI to dramatically reduce timelines, cost, and risk in bringing new therapies to patients.
Rakovina, with Dr. Artem Cherkasov as their Senior Scientific Advisor, leverages this same power through exclusive access to proven AI platforms (Deep Docking™ & Enki™) that position us at the forefront of cancer innovation.
"The democratization of drug discovery requires AI-based pipelines that are orders of magnitude faster and cheaper." - Dr. Artem Cherkasov, Senior AI & Medicinal Chemistry Advisor at Rakovina Therapeutics
DR. CHERKASOV: THE AI DRUG DISCOVERY PIONEER
When the world needed COVID-19 solutions fast, Dr. Artem Cherkasov's AI platform delivered—“It took us 19 days to complete the Deep Docking of 40 billion compounds. This formerly would have taken 10 years with the fastest available technology", says Dr. Cherkasov. He's since has built the most successful AI drug discovery platform in academic history.
Creator of Deep Docking™ - the original AI engine that screened 1.3 billion compounds in under a month
$142M Roche deal - largest in University of British Columbia's history
8 successful drug candidates licensed to major pharmaceutical companies
200+ research papers, and 80+ patents filed
With Dr. Cherkasov’s visionary leadership and proprietary AI technology at our core, Rakovina is uniquely positioned to deliver the next wave of breakthrough cancer therapies.
AI VS TRADITIONAL DRUG DEVELOPMENT
While traditional drug development takes 4-6 years and billions of dollars to reach clinical trials, Rakovina's AI-powered approach compresses this timeline to 9-12 months—transforming thousands of potential compounds into billions of possibilities with dramatically reduced time, cost, and risk.
Unique Opportunity
Dr. Cherkasov's Deep Docking technology has already proven its commercial value in the real world.
First-generation success: Deep Docking identified a breakthrough compound that Roche licensed for $142M—validating the commercial potential of AI drug discovery
Second-generation advantage: Rakovina now has exclusive access to the enhanced Deep Docking 2.0 platform.
Exclusive AI Edge
Rakovina holds exclusive commercial rights to Dr. Cherkasov's breakthrough AI platforms for DNA-damage response drug discovery
Sole licensee of Deep Docking™ 2.0 and Enki™ platforms for DDR drug discovery
Screens billions of compounds at 100× speed, delivering 6,000× enrichment
Rapid Progression to Preclinical Development
Rakovina's AI-powered approach has generated a robust pipeline of cancer-fighting compounds, each targeting specific vulnerabilities in tumor DNA repair mechanisms.
kt-3000 series: Advanced candidate targeting aggressive cancers including breast, ovarian, and prostate tumors
kt-2000 & kt-5000 series: Next-generation compounds in development, designed for enhanced effectiveness and safety
Rakovina's direct access to UBC's state-of-the-art facilities allows us to immediately test AI-predicted molecules, creating a high-velocity pipeline from digital discovery to preclinical assets.
Immediate validation of AI-discovered compounds through UBC's advanced wet-lab facilities
Continuous feedback loop between AI predictions and laboratory results speeds lead development
The DNA-damage response market represents one of the fastest-growing opportunities in oncology.
Market validation: Recent deals like the $1.5B Artios-Novartis and $1.2B Remix-Sanofi partnerships prove the immense commercial value of DDR-targeting therapies
Competitive positioning: Rakovina's exclusive access to Dr. Cherkasov's proven AI platform—which has already generated $142M in licensing deals—positions us to capture significant market share
Download Investor Kit — It’s free
Rakovina's success is driven by a world-class team that combines decades of cancer research expertise with proven AI innovation. Our leadership has a track record of transforming breakthrough science into commercial success.
Artem Cherkasov, PhD: Creator of Deep Docking with 200+ research papers, 80+ patents, and 8 successful drug licenses generating over $142M in deals
Petra Hamerlik, PhD: Former AstraZeneca DDR program director with deep expertise in translating DNA-damage response research into therapeutic breakthroughs
Download Investor Kit — It’s free
NEWS
The World’s Premier Cancer Research Forum
Rakovina (TSX-V: RKV) was selected to present groundbreaking preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting, the world’s premier cancer research forum.
The company unveiled two revolutionary studies :
PARP1-Selective Inhibitors for Brain Tumors
CNS-Penetrating ATR Inhibitors
Our Vision
Our mission is to deliver hope to patients and families by creating therapies that extend lives, improve outcomes, and redefine possibilities in cancer treatment.
Recent
Milestones
Oversubscribed private placement closed in 2025.
Partnerships with UBC, Dr. Cherkasov, and Variational AI accelerate discovery efforts.
Named among the Top Undervalued Biotech Stocks on the TSX Venture Exchange.
Download Investor Kit — It’s free